Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890574763> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2890574763 endingPage "TPS5095" @default.
- W2890574763 startingPage "TPS5095" @default.
- W2890574763 abstract "TPS5095 Background: The clinical activity of PARPi in patients with homologous recombination DNA-repair mutations and metastatic prostate cancer has now been established. Focusing specifically on patients with a germline mutation in a pre-specified group of DNA-repair genes, we hypothesize that targeted therapy with PARPi should be sufficient to induce a clinical response irrespective of hormonal (castration-sensitive/resistant) status. For men with metastatic hormone sensitive prostate cancer (mHSPC), this trial would also provide an alternative to ADT. Methods: This study is a multi-center, open-label, single arm Phase II trial. Eligible patients are those with mHSPC without prior ADT. All patients must have a documented germline mutation in a homologous recombination DNA-repair gene (BRCA1, BRCA2, ATM, CHEK2, NBN, RAD50, RAD51C, RAD51D, PALB2, MRE11, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM). Patients on trial must be ineligible for or decline standard-of-care hormonal treatment. A mandatory tumor biopsy will be performed prior to therapy. A second, optional tumor biopsy is planned after three months of therapy. Patients will be treated with Rucaparib 600mg po twice daily. Patients will be followed monthly with clinic visits and safety labs with PSA. The primary endpoint is the proportion of patients with a ≥ 50% decrease in PSA from baseline (PSA50 response). A total enrollment of 30 patients is planned to detect an improved PSA50 response rate from 50% to 75% with 90% power (one sided type I error of 0.1). The total number of patients allowed with a non-BRCA1, -BRCA2, or –ATM mutations will be capped at 10. For patients who do not respond to PARPi, we have incorporated safety rules into the study design to take patients off study at first signs of progression. Secondary endpoints include safety, progression-free survival, and objective response. Exploratory analysis will involve biomarker discovery including somatic DNA mutation analysis, RNA expression analysis, and immunohistochemistry for DNA damage markers. Clinical trial information: NCT03413995." @default.
- W2890574763 created "2018-09-27" @default.
- W2890574763 creator A5008552473 @default.
- W2890574763 creator A5018645768 @default.
- W2890574763 creator A5045477158 @default.
- W2890574763 creator A5051960511 @default.
- W2890574763 creator A5061239169 @default.
- W2890574763 creator A5080102032 @default.
- W2890574763 creator A5083333223 @default.
- W2890574763 date "2018-05-20" @default.
- W2890574763 modified "2023-10-18" @default.
- W2890574763 title "Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH)." @default.
- W2890574763 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.tps5095" @default.
- W2890574763 hasPublicationYear "2018" @default.
- W2890574763 type Work @default.
- W2890574763 sameAs 2890574763 @default.
- W2890574763 citedByCount "5" @default.
- W2890574763 countsByYear W28905747632020 @default.
- W2890574763 countsByYear W28905747632022 @default.
- W2890574763 countsByYear W28905747632023 @default.
- W2890574763 crossrefType "journal-article" @default.
- W2890574763 hasAuthorship W2890574763A5008552473 @default.
- W2890574763 hasAuthorship W2890574763A5018645768 @default.
- W2890574763 hasAuthorship W2890574763A5045477158 @default.
- W2890574763 hasAuthorship W2890574763A5051960511 @default.
- W2890574763 hasAuthorship W2890574763A5061239169 @default.
- W2890574763 hasAuthorship W2890574763A5080102032 @default.
- W2890574763 hasAuthorship W2890574763A5083333223 @default.
- W2890574763 hasConcept C104317684 @default.
- W2890574763 hasConcept C111425858 @default.
- W2890574763 hasConcept C121608353 @default.
- W2890574763 hasConcept C126322002 @default.
- W2890574763 hasConcept C134935766 @default.
- W2890574763 hasConcept C13514818 @default.
- W2890574763 hasConcept C143998085 @default.
- W2890574763 hasConcept C2776071976 @default.
- W2890574763 hasConcept C2778124228 @default.
- W2890574763 hasConcept C2778144015 @default.
- W2890574763 hasConcept C2778993383 @default.
- W2890574763 hasConcept C2780192828 @default.
- W2890574763 hasConcept C501734568 @default.
- W2890574763 hasConcept C502942594 @default.
- W2890574763 hasConcept C526805850 @default.
- W2890574763 hasConcept C54355233 @default.
- W2890574763 hasConcept C60748783 @default.
- W2890574763 hasConcept C71924100 @default.
- W2890574763 hasConcept C86803240 @default.
- W2890574763 hasConceptScore W2890574763C104317684 @default.
- W2890574763 hasConceptScore W2890574763C111425858 @default.
- W2890574763 hasConceptScore W2890574763C121608353 @default.
- W2890574763 hasConceptScore W2890574763C126322002 @default.
- W2890574763 hasConceptScore W2890574763C134935766 @default.
- W2890574763 hasConceptScore W2890574763C13514818 @default.
- W2890574763 hasConceptScore W2890574763C143998085 @default.
- W2890574763 hasConceptScore W2890574763C2776071976 @default.
- W2890574763 hasConceptScore W2890574763C2778124228 @default.
- W2890574763 hasConceptScore W2890574763C2778144015 @default.
- W2890574763 hasConceptScore W2890574763C2778993383 @default.
- W2890574763 hasConceptScore W2890574763C2780192828 @default.
- W2890574763 hasConceptScore W2890574763C501734568 @default.
- W2890574763 hasConceptScore W2890574763C502942594 @default.
- W2890574763 hasConceptScore W2890574763C526805850 @default.
- W2890574763 hasConceptScore W2890574763C54355233 @default.
- W2890574763 hasConceptScore W2890574763C60748783 @default.
- W2890574763 hasConceptScore W2890574763C71924100 @default.
- W2890574763 hasConceptScore W2890574763C86803240 @default.
- W2890574763 hasIssue "15_suppl" @default.
- W2890574763 hasLocation W28905747631 @default.
- W2890574763 hasOpenAccess W2890574763 @default.
- W2890574763 hasPrimaryLocation W28905747631 @default.
- W2890574763 hasRelatedWork W2740625513 @default.
- W2890574763 hasRelatedWork W3004361286 @default.
- W2890574763 hasRelatedWork W3013492213 @default.
- W2890574763 hasRelatedWork W4212764788 @default.
- W2890574763 hasRelatedWork W4282977821 @default.
- W2890574763 hasRelatedWork W4292065534 @default.
- W2890574763 hasRelatedWork W4313648097 @default.
- W2890574763 hasRelatedWork W4322775472 @default.
- W2890574763 hasRelatedWork W4361957646 @default.
- W2890574763 hasRelatedWork W4361959755 @default.
- W2890574763 hasVolume "36" @default.
- W2890574763 isParatext "false" @default.
- W2890574763 isRetracted "false" @default.
- W2890574763 magId "2890574763" @default.
- W2890574763 workType "article" @default.